Scarica l'app Stockscreener
52.26
2.23%
-1.19
Dopo l'orario di chiusura:
52.25
-0.010
-0.02%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRSP Giù?
Forum
Previsione
Crispr Therapeutics Ag Borsa (CRSP) Ultime notizie
GOOG: Alphabet IncOrdinary SharesClass C Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Trading Systems Reacting to (CRSP) Volatility - Stock Traders Daily
Why CRISPR Therapeutics Stock Rocked the Market Last Month - The Motley Fool
Why CRISPR Therapeutics Stock Rocked the Market Last Month - The Motley Fool
CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference - markets.businessinsider.com
Where Will CRISPR Therapeutics Stock Be in 5 Years? - fool.com
Morgan Stanley's healthcare conference will feature CRISPR Therapeutics on Sept. 14 - Stock Titan
Raiffeisen Bank International AG Buys Shares of 20,000 CRISPR Therapeutics AG $CRSP - MarketBeat
Shah Wealth Advisors LLC Buys New Position in CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics: CASGEVY Validates The Platform, Strengthening The Acquisition Case - Seeking Alpha
CRSP News | CRISPR THERAPEUTICS AG (NASDAQ:CRSP) - ChartMill
2 Reasons CRISPR Therapeutics Stock Could Soar in the Final 4 Months of 2026 - The Motley Fool
Why Is CRISPR Therapeutics (CRSP) Up 7.1% Since Last Earnings Report? - Yahoo Finance
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Citizens reiterates CRISPR Therapeutics stock rating on gene therapy data By Investing.com - Investing.com Nigeria
CRISPR Therapeutics' (CRSP) Market Outperform Rating Reiterated at Citizens Jmp - MarketBeat
H.C. Wainwright reiterates CRISPR Therapeutics stock rating at buy - Investing.com
Citizens reiterates CRISPR Therapeutics stock rating on gene therapy data - Investing.com
Crispr Therapeutics AG (CRSP) Gets a Buy from William Blair - theglobeandmail.com
CRISPR Therapeutics Presents One-Year Durability Data for CTX310 at ESC Congress 2026 - Quiver Quantitative
CRISPR Therapeutics Presents Phase 1a Data for CTX310® - GlobeNewswire
CRISPR Therapeutics' one infusion kept triglycerides and LDL lower for a year - Stock Titan
CRISPR Therapeutics (CRSP) Is Up 15.0% After Casgevy Label ExpansionWhat's Changed - Sahm
CRISPR Therapeutics (NASDAQ:CRSP) Trading 6.6% HigherHere's What Happened - MarketBeat
4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains - TradingView
CRISPR Therapeutics Stock Is Up Only 8% This Year. Is Cathie Wood's Bet on the Gene-Editing Stock Dead Money? - The Motley Fool
CRISPR Therapeutics Soars On Gene Therapy Breakout - TipRanks
Recursion, Novavax, Crispr Therapeutics Stocks Slip Premarket After Cancer Therapy RallyRecursion Phar - Benzinga
CRISPR Therapeutics AG (NASDAQ:CRSP) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Trading Up 11.2%Time to Buy? - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Why CRISPR Therapeutics Is Suddenly Back In Focus - TipRanks
CRISPR Therapeutics AG (CRSP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CRISPR Therapeutics (CRSP): Orbis-led investors disclose 5.6% ownership stake - Stock Titan
Stronger Revenue and Narrower Loss Might Change The Case For Investing In CRISPR Therapeutics (CRSP) - Sahm
Bank of America Corp DE Decreases Stock Position in CRISPR Therapeutics AG $CRSP - MarketBeat
CRSP Stock Climbs After-Hours As CRISPR Maps Busy Second-Half Pipeline After Upbeat Q2 - stocktwits.com
CRISPR Therapeutics (CRSP) Stock Looks Fairly Valued Despite Pipeline Promise - Sahm
CRISPR Therapeutics (CRSP) CFO Prasad Raju makes bona fide gift of 750 shares - Stock Titan
CRISPR Therapeutics AG (CRSP) Stock Forecasts - Yahoo! Finance Canada
CRISPR Therapeutics AG $CRSP Stock Position Raised by Quantinno Capital Management LP - MarketBeat
Crispr Therapeut (CRSP) Stock News & Updates - Stock Titan
CRISPR Therapeutics (CRSP) Earnings Drew Fresh Interest, Is The Stock Below Fair Value? - Sahm
CRISPR Therapeutics (NASDAQ:CRSP) Rating Increased to Hold at Wall Street Zen - MarketBeat
CRISPR Therapeutics AG (CRSP) Stock News Today - TradingKey
Goldman Sachs Keeps Their Hold Rating on Crispr Therapeutics AG (CRSP) - The Globe and Mail
HC Wainwright Has Positive Forecast for CRSP FY2026 Earnings - MarketBeat
California State Teachers Retirement System Increases Stock Position in CRISPR Therapeutics AG $CRSP - MarketBeat
Brave Asset Management Inc. Cuts Stake in CRISPR Therapeutics AG $CRSP - MarketBeat
Dimensional Fund Advisors LP Sells 412,889 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
RBC Capital Keeps Their Hold Rating on Crispr Therapeutics AG (CRSP) - The Globe and Mail
CRISPR Therapeutics AG (NASDAQ:CRSP) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates - simplywall.st
Why CRISPR Therapeutics (CRSP) Is Up 11.6% After CASGEVY Expansion And Pipeline UpdatesAnd What's Next - webull.com
CRISPR: "Strong Buy" CASGEVY Sales Growth And In Vivo Expansion With CTX310 (NASDAQ:CRSP) - Seeking Alpha
Piper Sandler Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP) - The Globe and Mail
Citi Raises Price Target for CRISPR Therapeutics (CRSP) Amid Str - GuruFocus
CRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates - finance.yahoo.com
CRISPR Therapeutics AG Stock 12‑Month Price Target Raised to $84.39, Implies 70% Upside - TradingView
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):